Identification of the rs9277534 HLA-DP expression marker by next generation sequencing for the selection of unrelated donors for hematopoietic cell transplantation.


Journal

Human immunology
ISSN: 1879-1166
Titre abrégé: Hum Immunol
Pays: United States
ID NLM: 8010936

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 11 03 2019
revised: 10 05 2019
accepted: 23 05 2019
pubmed: 10 6 2019
medline: 27 2 2020
entrez: 10 6 2019
Statut: ppublish

Résumé

Mismatching of an unrelated donor against a high-expression HLA-DPB1 recipient allele is associated with a high risk of graft-versus-host disease and mortality. The Seattle Cancer Care Alliance (SCCA) and Fred Hutchinson Cancer Research Center transplant program employs an algorithm to match for HLA-A, B, C, DRB1, DQB1 and DPB1 alleles (12/12) and to avoid, whenever possible, donor mismatching against a recipient high-expression HLA-DPB1 allele. HLA-DPB1 expression is associated with the rs9277534 A/G polymorphism located in the 3'UTR of the HLA-DPB1 gene. Next generation sequencing of HLA-DPB1 using the Illumina TruSight HLA V2 Sequencing Panel and Conexio Assign software analyses provides information on rs9277534 variants without the need for any additional SNP testing. Here we present the molecular location of rs9277534 in NGS data and discuss the challenges to resolve HLA-DPB1 ambiguities.

Identifiants

pubmed: 31176504
pii: S0198-8859(19)30273-3
doi: 10.1016/j.humimm.2019.05.010
pii:
doi:

Substances chimiques

3' Untranslated Regions 0
HLA-DP beta-Chains 0
HLA-DPB1 antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

828-833

Informations de copyright

Copyright © 2019 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Auteurs

Gansuvd Balgansuren (G)

Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA; University of Washington, Seattle, WA, USA. Electronic address: gbalgans@seattlecca.org.

Lois Regen (L)

Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA.

Maggie Sprague (M)

Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA.

Nakita Shelton (N)

Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA.

Effie Petersdorf (E)

Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA.

John A Hansen (JA)

Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH